Gain Therapeutics price target lowered to $6 from $7 at Roth Capital

Roth Capital lowered the firm’s price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a Buy rating on the shares after meeting with its CEO to discuss the company’s Phase 1b study evaluating lead candidate GT-02287 in Parkinson’s disease. The CSF biomarker data expected in Q4 makes most sense “to gain preliminary conviction” as it better capitulates pathological changes associated with iPD and GBA1-PD vs. serum biomarker analysis, the analyst tells investors in a research note.